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Strengths and limitations of this study
 ► This will be a comprehensive review of risk models 
and scores for predicting metabolic syndrome.
 ► Will identify good and poor risk models and scores 
according to the predicting performance of a model.
 ► Use of methods that are applicable to reviews of any 
risk models and scores.
 ► May involve screening large numbers of abstracts at 
the initial stages due to lack of a sensitive literature 
search strategy.
 ► Important additional findings might be missed 
by limiting the review to only papers published in 
English.
AbStrACt
Introduction Metabolic syndrome ‘a clustering of risk 
factors which includes hypertension central obesity, 
impaired glucose metabolism with insulin resistance 
and dyslipidaemia’ affects approximately 20%–25% of 
the global adult population. Individuals with metabolic 
syndrome have two to threefold risk of developing 
cardiovascular disease and a fivefold risk of developing 
developing diabetes and death from all causes. Although 
there is rapid proliferation of risk scores for predicting 
the risk of developing metabolic syndrome later in life, 
yet, these are seldom used in the practice. Therefore, the 
purpose of this review is to determine the performance 
of risk models and scores for predicting the metabolic 
syndrome.
Methods and analysis Articles will be sought for from 
electronic databases (MEDLINE, CINAHL, PubMed and 
Web of Science) as well as the Cochrane Library. Further 
manual search of reference lists and grey literatures 
will be conducted. The search will cover from the start 
of indexing to 3 October 2018. Identified studies will be 
included if they fulfil the study selection criteria. Quality of 
studies will be appraised using suitable criteria for the risk 
models. The risk scores in the final sample of the review 
will be ranked/prioritised based on previous quality criteria 
for prognostic risk models. Lastly, the impact of the models 
will be ascertained by tracking citations on Google Scholar.
Ethics and dissemination This study does not require 
formal ethical approval as primary data will not be 
collected. The results will be disseminated through a 
peer-reviewed publication and relevant conference 
presentations.
PrOSPErO registration number CRD42019139326
IntrOduCtIOn
Metabolic syndrome (MetS) ‘a clustering 
of risk factors which includes hypertension, 
central obesity, impaired glucose metabolism 
with insulin resistance and dyslipidaemia’1 is 
common in most countries of the world.2 The 
global prevalence of MetS is approximately 
20%–25% of the adult population2 and this 
is believed to be increasing due to the factors 
such as ageing population, increase in life 
expectancy, poor dietary habits, sedentary 
life style and obesity.3 4 Furthermore, indi-
viduals with MetS have two to threefold risk 
of developing cardiovascular disease (CVD) 
and a fivefold risk of developing diabetes 
(DM).5 They would, therefore, add to the 
422.7 million and 230 million people with 
CVD and DM worldwide, respectively.6 7 It is, 
therefore, imperative that suitable preventa-
tive strategies are adopted in a systematic way 
to reduce the increasing burden of MetS-re-
lated morbidity and mortality.
Furthermore, MetS constitutes a major 
public health problem,2 and therefore, there 
is a need for urgent development of effective 
approaches for preventing and managing the 
syndrome.8 This is necessary for proper plan-
ning of health services, as well as for building 
the evidence base required to inform public 
health policies aimed at reducing the burden 
of the syndrome and downstream diseases 
and deaths relating to it.
Risk models simplify reality by estimating 
the degree to which health or disease is 
affected through a change in one or more 
risk factors.9 With increasing availability of 
datasets, computational power and statis-
tical methods, modelling is becoming more 
popular in chronic disease research.10 11 This 
no doubt has a key role to play in informing 
how the increasing burden of MetS on popu-
lation health can be addressed. Recently, 
there is proliferation of models and scores for 
assessing risk of developing MetS, however, to 
the best of our knowledge, none is in routine 
use either by clinicians or public health prac-
titioners and there is no available systematic 
review in the academic literature. This may 
present a confusing picture for both clinicians, 
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public health specialists and policy-makers, who would be 
potentially faced with a very complex literature, multiple 
different methodologies and probably very few studies of 
use in real life. Therefore, the purpose of this review is to 
determine the performance of risk models and scores for 
predicting MetS.
research question
What is the performance of risk models and scores for 
predicting MetS?
MEthOdS And dESIgn
Selection criteria
According to Wakefield,12 eligibility criterion is a process 
of determining the acceptability of a study by carefully 
defining which studies and samples can be included in 
a given review. Additionally, setting inclusion criteria 
provides a framework which enables researchers to limit 
bias thereby ensuring the validity of the research as well 
as access to data via process that is strictly accurate.13 The 
inclusion criteria for this review are as follows:
Inclusion
Study design: this review will include any study deriving or 
validating a risk model or score for MetS.
Population: as there are studies of MetS risk scores in 
both children and adults, this study will include studies 
focusing on any age group.
Intervention/control: this review will focus on studies 
that develop models or scoring systems based on MetS 
risk factors to predict temporal risk of MetS and/or vali-
dation of an MetS risk model or score.
Outcomes: Any related predictive outcomes (discrimina-
tion and calibration inclusive).
Exclusion
This study will exclude the following:
1. Studies that are still recruiting participants.
2. Studies investigating one or more single risk factors 
which are not connected to build a model or score.
3. Studies on screening and early detection.
4. Studies of models that predict genetic mutations rath-
er than MetS.
5. Studies conducted on animals.
PAtIEnt/PublIC InvOlvEMEnt
As this study does not involve human subjects, no patients 
will be involved.
Search strategy
This study will adopt mixed search strategy which will 
involve searching both electronic and manual databases 
in order to identify relevant studies for inclusion.14 15 The 
help of the IHR specialist librarian will be sought for 
while designing the search strategy and the final search 
strategy will be double checked by authors DP, GR and YP.
The proposed keywords for the literature search 
include: predict, screen, risk, score, MetS, insulin resis-
tance syndrome, syndrome X, model, regression, risk 
assessment, risk factor, calculator, analysis, sensitivity 
and specificity, receiver operating characteristic and OR. 
Eligible studies will be searched for systematically using 
synonym free-text words. Also, Truncation commands, 
Boolean and proximity operators will be used when 
conducting the searches and adapted in line with the 
interface used. Search will be limited to English language, 
but no restriction on publication date will be applied. 
Samples of the proposed search strategy can be found in 
online supplementary additional files 1 and 2.
The literature search will be carried out in databases 
such as CINAHL, MEDLINE, Web of Science and PubMed. 
The use of multiple databases minimises selection bias of 
articles.16 Also, MESH search will be performed in the 
Cochrane Library for MetS and risk. The search will cover 
from the start of indexing to 3 October 2018.
Additionally, manual search of the reference lists of 
all the selected articles will be conducted in order to 
identify more relevant articles. Furthermore, relevant 
‘grey literature’—research and materials produced by 
organisations that are not under control of the usual 
commercial or academic publishers—will be searched 
for in the following: The Grey Literature Report (http://
www. greylit. org/), OpenGrey ( www. opengrey. eu/) and 
OAISTER (http://www. oaister. org/). However, the grey 
literature search will be limited to abstracts, conferences, 
relevant stakeholder organisations and reports. Also, to 
ensure that newly published articles are not missed, Web 
of Science will be used for forward tracking of previous 
key published articles. Additionally, PubMed’s ‘My NCBI’ 
email alert system will be applied using a basic search 
strategy. Lastly, a complete update search on all the stated 
databases will be conducted 4 weeks before the final 
submission of the review draft. In the event that new arti-
cles fit for inclusion are detected, they will be evaluated 
and the findings incorporated in the review before the 
final submission.
Finally, search results from the various sources will be 
imported into Endnote V.8 ( endnote. com) and merged. 
Thereafter, duplicates will be screened and removed both 
electronically and manually.
Selection of studies
After identification of articles from searching electronic 
databases, one author (MSI) will conduct screening 
of their titles and abstracts according to the eligibility 
criteria. Subsequently, a second review author (DP) will 
conduct a check on a random sample of 10% of those 
screened articles. Furthermore, the full text papers of all 
the potentially eligible studies will be obtained (including 
those identified via non-electronic means). Review author 
(MSI) will then apply the full inclusion criteria to the full 
text articles and in event of any confusion/difficulty; this 
will be discussed with review authors (DP) (GR) and (YP). 
The review will be carried out using ‘Preferred Reporting 
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Items for Systematic Reviews and Meta-Analyses Protocols 
(PRISMA) checklist,17 PRISMA flow diagram will be used 
to show the selection process and Endnote V.8 ( endnote. 
com) will be used for managing references.
Quality assessment
The Prediction study Risk Of Bias Assessment Tool18, a 
tool for assessing the risk of bias and applicability of prog-
nostic model studies, will be used by review author (MSI) 
to appraise the individual studies. Difficulties encoun-
tered will be discussed and resolved with review authors 
(DP, GR and YP).
data extraction and management
Review author (MSI) will extract data using a standard 
form adopted from a similar study19 (see online addi-
tional file 3) and saved in Microsoft Excel 2016. Data to 
be extracted will be on the details specific to the review 
question and that satisfies the conditions for the narrative 
synthesis. The extracted data will be double checked by 
review authors (DP, GR and YP) and all conflicts will be 
resolved.
AnAlySIS
data synthesis (data analysis plan)
Although similar metabolic risk factors are used in defining 
MetS criteria, yet, they differ in terms of the cut-off levels 
of the basic components, the emphasis given to particular 
components or the pathophysiological basis underpinning 
the clustering.20 However, this lack of universally acceptable 
definition makes it difficult to compare different studies. 
Therefore, in this review, studies reporting prognostic 
models will be summarised using narrative synthesis due 
to anticipated heterogeneity of data across the studies (this 
potentially precludes a formal meta-analysis). The narrative 
synthesis will first report the number of studies to be included 
in the review, and then describe the characteristics of those 
studies including the study population and location. Subse-
quently, the statistical properties of the models—what vari-
ables (prognostic factors) were included in the final model; 
how the included variables were coded; what the specifica-
tion of the model was and how it produces an individual 
outcome probability or risk score; the reported predictive 
accuracy of the model (reported measures of discrimina-
tion and calibration); and whether the model was validated 
internally and/or externally, and if so, how?. Finally, the 
narrative synthesis will report the observed similarities and 
differences of findings, reflect on strength of findings and 
evaluate between study heterogeneity. All data analyses will 
be conducted separately for children and adults.
The risk scores in the final sample of the review will be 
ranked/prioritised based on previous quality criteria for 
prognostic risk models.21 Studies will be favoured based 
on their generalisability (externally validated by a separate 
research team on a different population) and usability (cali-
bration that is statistically significant, and discrimination 
above 0.70).
IMPACt AnAlySIS
The impact of each prediction model in the final sample 
will be assessed based on the following: ‘any description 
in the paper of use of the score beyond the population 
for whom it was developed and validated; number of cita-
tions of the paper in Google Scholar and number of these 
that described use of the score in an impact study; and 
critical appraisal of any impact studies identified on this 
citation track’.19 The guiding question of this phase of the 
review is: what is the evidence that this risk score has been 
used in an intervention which improved (or sought to 
improve) outcomes for individuals at high risk of MetS?
COnCluSIOn
This systematic review will be the first to assess the 
performance of existing risk scores for predicting MetS. 
It is expected that the findings of this review will be an 
important step towards informing the choice of poten-
tial MetS risk score both in clinical and public health 
decision-making. Particularly, the review will identify 
the various MetS risk scores currently in existence and 
examine their methodological strengths. Furthermore, 
the impact that the individual models had to practise so 
far will be investigated. Lastly, the identified risk scores 
will be ranked using standardised procedure in order to 
aid their selection by potential users.
Study status
The study is ongoing and is expected to be completed by 
September 2019.
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